溢价超三倍、新增5亿元商誉，爱博医疗押宝德美医疗

Core Viewpoint - Aibo Medical (688050), a leading ophthalmic device company, plans to enter the sports medicine sector through the acquisition of 68.31% of Demai Medical for 683 million yuan, with a significant premium over net asset value, expected to create approximately 500 million yuan in goodwill [1][7]. Group 1: Acquisition Details - The acquisition price of 683 million yuan represents about three times the net asset value of Demai Medical, with the transaction expected to generate around 500 million yuan in goodwill [1][7]. - Funding for the acquisition will primarily come from bank loans, estimated to cover 70% to 80% of the transaction value [4][5]. - Following the acquisition, Demai Medical will become a wholly-owned subsidiary of Aibo Medical, fully integrated into its consolidated financial statements [4]. Group 2: Financial Performance and Projections - Demai Medical, a leading player in the sports medicine field, is projected to achieve rapid revenue and net profit growth, with expected revenues of 236 million yuan and 286 million yuan for 2024 and 2025, respectively [9]. - Aibo Medical's revenue for the first three quarters of 2025 was 1.144 billion yuan, a year-on-year increase of 6.43%, while net profit decreased by 8.64% due to declining sales in artificial lenses and contact lenses [9]. - The acquisition is anticipated to enhance Aibo Medical's revenue and gross margin, optimizing its strategic positioning in the market [9]. Group 3: Market Context and Strategic Rationale - The sports medicine sector is experiencing rapid growth, driven by increasing demand from the aging population and supportive government policies, presenting a significant opportunity for Aibo Medical [10]. - Aibo Medical aims to leverage synergies in R&D, manufacturing, and sales channels through this acquisition, which is expected to provide new growth momentum amid slowing performance in its core ophthalmic business [1][10]. - The acquisition aligns with Aibo Medical's strategy to diversify its portfolio and tap into high-growth markets, contrasting with the more competitive and slower-growing ophthalmic sector [10].